{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T03:04:36Z","timestamp":1787367876002,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universitat de Valencia"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hypoxia is a key feature of solid tumors, contributing to therapeutic resistance and poor prognosis. Targeting hypoxic environments presents an opportunity to enhance drug delivery selectivity and improve treatment outcomes. Among nanocarriers, mesoporous silica nanoparticles (MSNs) have demonstrated great potential for drug delivery; however, achieving precise control over drug release remains a challenge. In this work, we develop an enzyme-responsive MSN system for targeted drug delivery in hypoxic tumors. MSNs were loaded with the chemotherapeutic drug doxorubicin (Dox) and capped with an azobenzene (Azo) gatekeeper. The bulky Azo group acts as a responsive molecular gate that remains closed under normoxic conditions but undergoes enzymatic cleavage by azoreductases, which are overexpressed in hypoxic tumor microenvironment. This cleavage triggers the uncapping of the pores, inducing the release of Dox specifically in the hypoxic region, minimizing premature drug leakage and off-target toxicity. In vitro studies with A549 cells (which overexpress azoreductase) and THP-1 cells (with low expression of azoreductases) under normoxic and hypoxic conditions, demonstrated a significant increase in Dox release and cytotoxicity in the A549 cells compared with the THP-1, which was more pronounced under hypoxia. These findings highlight the potential of enzyme-responsive MSNs as a promising strategy for selective drug delivery in hypoxic tumors.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1007\/s13346-025-01950-5","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T20:43:13Z","timestamp":1756500193000},"page":"1423-1434","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Mesoporous silica nanoparticles with an azobenzene gatekeeper as hypoxia-responsive nanocarriers for targeted doxorubicin delivery"],"prefix":"10.1007","volume":"16","author":[{"given":"Paula","family":"Rodrigo-Mart\u00ednez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Barros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Carmen","family":"Terencio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pau","family":"Arroyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"S\u00e1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Parra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8496-6448","authenticated-orcid":false,"given":"Pablo","family":"Gavi\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"1950_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"1950_CR2","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.trecan.2019.02.003","volume":"5","author":"N Chatterjee","year":"2019","unstructured":"Chatterjee N, Bivona TG. Polytherapy and targeted cancer drug resistance. Trends Cancer. 2019;5:170\u201382. https:\/\/doi.org\/10.1016\/j.trecan.2019.02.003.","journal-title":"Trends Cancer"},{"key":"1950_CR3","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","volume":"575","author":"N Vasan","year":"2019","unstructured":"Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575:299\u2013309. https:\/\/doi.org\/10.1038\/s41586-019-1730-1.","journal-title":"Nature"},{"key":"1950_CR4","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/nrc2397","volume":"8","author":"MW Dewhirst","year":"2008","unstructured":"Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer. 2008;8:425\u201337. https:\/\/doi.org\/10.1038\/nrc2397.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1950_CR5","doi-asserted-by":"publisher","first-page":"19350","DOI":"10.1038\/s41598-021-98638-w","volume":"11","author":"M Soltani","year":"2021","unstructured":"Soltani M, Souri M, Moradi Kashkooli F. Effects of hypoxia and nanocarrier size on pH-responsive nano-delivery system to solid tumors. Sci Rep. 2021;11(1):19350. https:\/\/doi.org\/10.1038\/s41598-021-98638-w.","journal-title":"Sci Rep"},{"issue":"312","key":"1950_CR6","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1259\/0007-1285-26-312-638","volume":"26","author":"LH Gray","year":"1953","unstructured":"Gray LH, Conger AD, Ebert M, Hornsey S, Scott OCA. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol. 1953;26(312):638\u201348. https:\/\/doi.org\/10.1259\/0007-1285-26-312-638.","journal-title":"Br J Radiol"},{"issue":"1","key":"1950_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-023-01332-8","volume":"8","author":"Z Chen","year":"2023","unstructured":"Chen Z, Han F, Du Y, Shi H, Zhou W. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2023;8(1):1\u201323. https:\/\/doi.org\/10.1038\/s41392-023-01332-8.","journal-title":"Signal Transduct Target Ther"},{"key":"1950_CR8","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrc1367","volume":"4","author":"JM Brown","year":"2004","unstructured":"Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 2004;4:437\u201347. https:\/\/doi.org\/10.1038\/nrc1367.","journal-title":"Nat Rev Cancer"},{"key":"1950_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/bjc.1998.430","volume":"77","author":"JM Brown","year":"1998","unstructured":"Brown JM. Exploiting tumour hypoxia and overcoming mutant p53 with Tirapazamine. Br J Cancer. 1998;77:12\u20134. https:\/\/doi.org\/10.1038\/bjc.1998.430.","journal-title":"Br J Cancer"},{"key":"1950_CR10","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/s0305-7372(03)00003-3","volume":"29","author":"AM Shannon","year":"2003","unstructured":"Shannon AM, Bouchier-Hayes DJ, Condron CM, Toomey D. Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev. 2003;29:297\u2013307. https:\/\/doi.org\/10.1016\/s0305-7372(03)00003-3.","journal-title":"Cancer Treat Rev"},{"key":"1950_CR11","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.yjmcc.2021.12.013","volume":"165","author":"AH Baik","year":"2022","unstructured":"Baik AH. Hypoxia signaling and oxygen metabolism in cardio-oncology. J Mol Cell Cardiol. 2022;165:64\u201375. https:\/\/doi.org\/10.1016\/j.yjmcc.2021.12.013.","journal-title":"J Mol Cell Cardiol"},{"key":"1950_CR12","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1093\/jnci\/93.4.266","volume":"93","author":"M H\u00f6ckel","year":"2001","unstructured":"H\u00f6ckel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 2001;93:266\u201376. https:\/\/doi.org\/10.1093\/jnci\/93.4.266.","journal-title":"J Natl Cancer Inst"},{"key":"1950_CR13","doi-asserted-by":"publisher","first-page":"964934","DOI":"10.3389\/fonc.2022.964934","volume":"12","author":"L Yong","year":"2022","unstructured":"Yong L, Tang S, Yu H, Zhang H, Zhang Y, Wan Y, Cai F. The role of hypoxia-inducible factor-1 alpha in multidrug-resistant breast cancer. Front Oncol. 2022;12:964934. https:\/\/doi.org\/10.3389\/fonc.2022.964934.","journal-title":"Front Oncol"},{"issue":"2","key":"1950_CR14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.canlet.2008.12.011","volume":"282","author":"L Khandrika","year":"2021","unstructured":"Khandrika L, Kumar B, Koul S, Maroni P, Koul HK. Oxidative stress in prostate cancer. Cancer Lett. 2021;282(2):125\u201336. https:\/\/doi.org\/10.1016\/j.canlet.2008.12.011.","journal-title":"Cancer Lett"},{"key":"1950_CR15","doi-asserted-by":"publisher","first-page":"682762","DOI":"10.3389\/fonc.2021.682762","volume":"11","author":"R Xu","year":"2021","unstructured":"Xu R, Luo X, Ye X, Li H, Liu H, Du Q, Zhai Q. SIRT1\/PGC-1\u03b1\/PPAR-\u03b3 correlate with Hypoxia-Induced chemoresistance in Non-Small cell lung cancer. Front Oncol. 2021;11:682762. https:\/\/doi.org\/10.3389\/fonc.2021.682762.","journal-title":"Front Oncol"},{"key":"1950_CR16","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/pon.1245","volume":"17","author":"J Lemieux","year":"2008","unstructured":"Lemieux J, Maunsell E, Provencher L. Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review. Psychooncology. 2008;17:317\u201328. https:\/\/doi.org\/10.1002\/pon.1245.","journal-title":"Psychooncology"},{"issue":"3","key":"1950_CR17","doi-asserted-by":"publisher","first-page":"627","DOI":"10.3390\/cancers14030627","volume":"14","author":"WMC van den Boogaard","year":"2022","unstructured":"van den Boogaard WMC, Komninos DSJ, Vermeij WP. Chemotherapy Side-Effects: not all DNA damage is equal. Cancers. 2022;14(3):627. https:\/\/doi.org\/10.3390\/cancers14030627.","journal-title":"Cancers"},{"issue":"3","key":"1950_CR18","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1039\/C8CS00304A","volume":"48","author":"A Sharma","year":"2019","unstructured":"Sharma A, Arambula JF, Koo S, Kumar R, Singh H, Sessler JL, Kim JS. Hypoxia-targeted drug delivery. Chem Soc Rev. 2019;48(3):725\u2013964. https:\/\/doi.org\/10.1039\/C8CS00304A.","journal-title":"Chem Soc Rev"},{"key":"1950_CR19","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.nano.2014.09.014","volume":"11","author":"Y Wang","year":"2015","unstructured":"Wang Y, Zhao Q, Han N, Bai L, Li J, Liu J, Che E, Hu L, Zhang Q, Jiang T, Wang S. Mesoporous silica nanoparticles in drug delivery and biomedical applications. Nanomedicine. 2015;11:313\u201327. https:\/\/doi.org\/10.1016\/j.nano.2014.09.014.","journal-title":"Nanomedicine"},{"key":"1950_CR20","doi-asserted-by":"publisher","first-page":"5365","DOI":"10.1039\/D1CS00659B","volume":"51","author":"M Vallet-Reg\u00ed","year":"2022","unstructured":"Vallet-Reg\u00ed M, Sch\u00fcth F, Lozano D, Colilla M, Manzano M. Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades? Chem Soc Rev. 2022;51:5365\u2013451. https:\/\/doi.org\/10.1039\/D1CS00659B.","journal-title":"Chem Soc Rev"},{"key":"1950_CR21","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.actbio.2024.01.002","volume":"176","author":"B Escriche-Navarro","year":"2024","unstructured":"Escriche-Navarro B, Garrido E, Sancen\u00f3n F, Garc\u00eda-Fern\u00e1ndez A, Mart\u00ednez-M\u00e1\u00f1ez R. A navitoclax-loaded nanodevice targeting matrix metalloproteinase-3 for the selective elimination of senescent cells. Acta Biomater. 2024;176:405\u201316. https:\/\/doi.org\/10.1016\/j.actbio.2024.01.002.","journal-title":"Acta Biomater"},{"issue":"3","key":"1950_CR22","doi-asserted-by":"publisher","first-page":"818","DOI":"10.3390\/nano11030818","volume":"11","author":"M Barros","year":"2021","unstructured":"Barros M, L\u00f3pez-Carrasco A, Amor\u00f3s P, Gil S, Gavi\u00f1a P, Parra M, El Haskouri J, Terencio MC, Costero AM. Chromogenic chemodosimeter based on capped silica particles to detect spermine and spermidine. Nanomaterials. 2021;11(3):818. https:\/\/doi.org\/10.3390\/nano11030818.","journal-title":"Nanomaterials"},{"key":"1950_CR23","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1021\/cm970128o","volume":"9","author":"A Sayari","year":"1997","unstructured":"Sayari A, Liu P, Kruk M, Jaroniec M. Characterization of Large-Pore MCM-41 molecular sieves obtained via hydrothermal restructuring. Chem Mater. 1997;9:2499\u2013506. https:\/\/doi.org\/10.1021\/cm970128o.","journal-title":"Chem Mater"},{"key":"1950_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics13060900","volume":"13","author":"T Moodley","year":"2021","unstructured":"Moodley T, Singh M. Dendrimer-Coated gold nanoparticles for efficient Folate-Targeted mRNA delivery in vitro. Pharmaceutics. 2021;13:1\u201319. https:\/\/doi.org\/10.3390\/pharmaceutics13060900.","journal-title":"Pharmaceutics"},{"key":"1950_CR25","doi-asserted-by":"publisher","first-page":"16014","DOI":"10.1038\/natrevmats.2016.14","volume":"1","author":"S Wilhelm","year":"2016","unstructured":"Wilhelm S, Tavares AJ, Dai Q, Ohta S, Audet J, Dvorak HF, Chan WCW. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016;1:16014. https:\/\/doi.org\/10.1038\/natrevmats.2016.14.","journal-title":"Nat Rev Mater"},{"key":"1950_CR26","doi-asserted-by":"publisher","first-page":"1902242","DOI":"10.1002\/smll.201902242","volume":"16","author":"A Garc\u00eda-Fern\u00e1ndez","year":"2020","unstructured":"Garc\u00eda-Fern\u00e1ndez A, Aznar E, Mart\u00ednez-M\u00e1\u00f1ez R, Sancen\u00f3n F. New advances in in vivo applications of gated mesoporous silica as drug delivery nanocarriers. Small. 2020;16:1902242. https:\/\/doi.org\/10.1002\/smll.201902242.","journal-title":"Small"},{"issue":"1","key":"1950_CR27","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3390\/s22010261","volume":"22","author":"M Parra","year":"2022","unstructured":"Parra M, Gil S, Gavi\u00f1a P, Costero AM. Mesoporous silica nanoparticles in chemical detection: from small species to large Bio-Molecules. Sensors. 2022;22(1):261. https:\/\/doi.org\/10.3390\/s22010261.","journal-title":"Sensors"},{"key":"1950_CR28","doi-asserted-by":"publisher","first-page":"2400353","DOI":"10.1002\/smll.202400353","volume":"20","author":"J Zhang","year":"2024","unstructured":"Zhang J, Zhou J, Tang L, Ma J, Wang Y, Yang H, Wang X, Fan W. Custom-Design of Multi-Stimuli-Responsive degradable silica nanoparticles for advanced Cancer-Specific chemotherapy. Small. 2024;20:2400353. https:\/\/doi.org\/10.1002\/smll.202400353.","journal-title":"Small"},{"key":"1950_CR29","doi-asserted-by":"publisher","first-page":"125326","DOI":"10.1016\/j.ijpharm.2025.125326","volume":"672","author":"M Barros","year":"2025","unstructured":"Barros M, S\u00e1ez JA, Arroyo P, Ros-Lis JV, Garrido MD, Mart\u00ednez-M\u00e1\u00f1ez R, Terencio MC, Montesinos MC, Gavi\u00f1a P. Nitroreductase-responsive gated mesoporous silica nanocarriers for hypoxia-targeted drug delivery. Int J Pharm. 2025;672:125326. https:\/\/doi.org\/10.1016\/j.ijpharm.2025.125326.","journal-title":"Int J Pharm"},{"issue":"28","key":"1950_CR30","doi-asserted-by":"publisher","first-page":"21454","DOI":"10.1016\/S0021-9258(18)42151-5","volume":"268","author":"Y Li","year":"1993","unstructured":"Li Y, Jaiswal K. Regulation of human NAD(P)H:quinone oxidoreductase gene. Role of AP1 binding site contained within human antioxidant response element. J Biol Chem. 1993;268(28):21454. https:\/\/doi.org\/10.1016\/S0021-9258(18)42151-5.","journal-title":"J Biol Chem"},{"key":"1950_CR31","doi-asserted-by":"publisher","first-page":"6407","DOI":"10.1021\/jacs.5b04097","volume":"137","author":"Y Li","year":"2015","unstructured":"Li Y, Sun Y, Li J, Su Q, Yuan W, Dai Y, Han C, Wang Q, Feng W, Li F. Ultrasensitive Near-Infrared Fluorescence-Enhanced probe for in vivo nitroreductase imaging. J Am Chem Soc. 2015;137:6407\u201316. https:\/\/doi.org\/10.1021\/jacs.5b04097.","journal-title":"J Am Chem Soc"},{"key":"1950_CR32","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.biomaterials.2016.11.023","volume":"115","author":"P Verwilst","year":"2017","unstructured":"Verwilst P, Han J, Lee J, Mun S, Kang HG, Kim JS. Reconsidering Azobenzene as a component of small-molecule hypoxia-mediated cancer drugs: a theranostic case study. Biomaterials. 2017;115:104\u201314. https:\/\/doi.org\/10.1016\/j.biomaterials.2016.11.023.","journal-title":"Biomaterials"},{"key":"1950_CR33","doi-asserted-by":"publisher","first-page":"13172","DOI":"10.1039\/C9CC06727B","volume":"55","author":"N Ding","year":"2019","unstructured":"Ding N, Li Z, Tian X, Zhang J, Guo K, Wang P. Azo-based near-infrared fluorescent theranostic probe for tracking hypoxia-activated cancer chemotherapy in vivo. Chem Comm. 2019;55:13172\u20135. https:\/\/doi.org\/10.1039\/C9CC06727B.","journal-title":"Chem Comm"},{"key":"1950_CR34","doi-asserted-by":"publisher","first-page":"5619","DOI":"10.1039\/D0PY00826E","volume":"11","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Wang Z, Wang Y, Li L, Zhou N, Cai Y, Zhang Z, Zhu X. Azoreductase-triggered fluorescent nanoprobe synthesized by RAFT-mediated polymerization-induced self-assembly for drug release. Polym Chem. 2020;11:5619\u201329. https:\/\/doi.org\/10.1039\/D0PY00826E.","journal-title":"Polym Chem"},{"key":"1950_CR35","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1021\/acs.biomac.6b00350","volume":"17","author":"P Kulkarni","year":"2016","unstructured":"Kulkarni P, Haldar MK, You S, Choi Y, Mallik S. Hypoxia-responsive polymersomes for drug delivery to hypoxic pancreatic cancer cells. Biomacromolecules. 2016;17:2507\u201313. https:\/\/doi.org\/10.1021\/acs.biomac.6b00350.","journal-title":"Biomacromolecules"},{"key":"1950_CR36","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.actbio.2018.03.013","volume":"71","author":"Z Xie","year":"2018","unstructured":"Xie Z, Guo W, Guo N, Huangfu M, Liu H, Lin M, Xu W, Chen J, Wang TT, Wei Q, Han M, Gao J. Targeting tumor hypoxia with stimulus-responsive nanocarriers in overcoming drug resistance and monitoring anticancer efficacy. Acta Biomater. 2018;71:351\u201362. https:\/\/doi.org\/10.1016\/j.actbio.2018.03.013.","journal-title":"Acta Biomater"},{"key":"1950_CR37","doi-asserted-by":"publisher","first-page":"6901","DOI":"10.1039\/c7nr00808b","volume":"9","author":"J Lee","year":"2017","unstructured":"Lee J, Oh E-T, Yoon H, Kim CW, Han Y, Song J, Jang H, Park HJ, Kim C. Mesoporous nanocarriers with a stimulus-responsive cyclodextrin gatekeeper for targeting tumor hypoxia. Nanoscale. 2017;9:6901\u201309. https:\/\/doi.org\/10.1039\/c7nr00808b.","journal-title":"Nanoscale"},{"key":"1950_CR38","doi-asserted-by":"publisher","first-page":"101543","DOI":"10.1016\/j.jddst.2020.101543","volume":"56","author":"EH Jang","year":"2020","unstructured":"Jang EH, Kim GL, Park MG, Shim MK, Kim J-H. Hypoxia-responsive, organic-inorganic hybrid mesoporous silica nanoparticles for triggered drug release. J Drug Deliv Sci Technol. 2020;56:101543. https:\/\/doi.org\/10.1016\/j.jddst.2020.101543.","journal-title":"J Drug Deliv Sci Technol"},{"key":"1950_CR39","doi-asserted-by":"publisher","first-page":"24377","DOI":"10.1021\/acsami.9b04142","volume":"11","author":"Q Yan","year":"2019","unstructured":"Yan Q, Guo X, Huang X, Meng X, Liu F, Dai P, Wang Z, Zhao Y. Gated mesoporous silica nanocarriers for hypoxia-responsive cargo release. ACS Appl Mater Interfaces. 2019;11:24377\u201385. https:\/\/doi.org\/10.1021\/acsami.9b04142.","journal-title":"ACS Appl Mater Interfaces"},{"key":"1950_CR40","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.nano.2014.09.014","volume":"11","author":"Y Wang","year":"2015","unstructured":"Wang Y, Zhao Q, Han N, Bai L, Li J, Liu J, Che E, Hu L, Zhang Q, Jiang T, Wang S. Mesoporous silica nanoparticles in drug delivery and biomedical applications. Nanomedicine:NBM. 2015;11:313\u201327. https:\/\/doi.org\/10.1016\/j.nano.2014.09.014.","journal-title":"Nanomedicine:NBM"},{"issue":"5","key":"1950_CR41","doi-asserted-by":"publisher","first-page":"519","DOI":"10.4172\/2157-7439.1000519","volume":"9","author":"N Zhao","year":"2018","unstructured":"Zhao N, Woodle MC, Mixson AJ. Advances in delivery systems for doxorubicin. J Nanomed Nanotechnol. 2018;9(5):519. https:\/\/doi.org\/10.4172\/2157-7439.1000519.","journal-title":"J Nanomed Nanotechnol"},{"key":"1950_CR42","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.3390\/nano5041906","volume":"5","author":"M Mart\u00ednez-Carmona","year":"2015","unstructured":"Mart\u00ednez-Carmona M, Colilla M, Vallet-Reg\u00ed M. Smart mesoporous nanomaterials for antitumor therapy. Nanomaterials. 2015;5:1906\u201337. https:\/\/doi.org\/10.3390\/nano5041906.","journal-title":"Nanomaterials"},{"issue":"18","key":"1950_CR43","doi-asserted-by":"publisher","first-page":"14246","DOI":"10.1039\/d4ra08830a","volume":"15","author":"D Szymczuk","year":"2025","unstructured":"Szymczuk D, Markiewicz KH, Niemirowicz-Laskowska K, Sawicka D, Misztalewska-Turkowicz I, Car H, Wilczewska AZ. Covalent modification of iron oxide-poly(lithocholic acid) nanoparticles with folic acid or doxorubicin - an approach for enhanced cancer therapy. RSA Adv. 2025;15(18):14246\u201358. https:\/\/doi.org\/10.1039\/d4ra08830a.","journal-title":"RSA Adv"},{"key":"1950_CR44","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ijpharm.2006.03.052","volume":"319","author":"S Azarmi","year":"2006","unstructured":"Azarmi S, Tao X, Chen H, Wang Z, Finlay WH, L\u00f6benberg R, Roa WH. Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles. Int J Pharma. 2006;319:155\u201361. https:\/\/doi.org\/10.1016\/j.ijpharm.2006.03.052.","journal-title":"Int J Pharma"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-01950-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-025-01950-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-01950-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T12:00:40Z","timestamp":1774958440000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-025-01950-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1950"],"URL":"https:\/\/doi.org\/10.1007\/s13346-025-01950-5","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"assertion":[{"value":"3 August 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors gave their consent for publication of this manuscript in this journal and the work has not been publishedand is not being considered for publication elsewhere.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}